MOSCOW, may 24 — RIA Novosti. Treatment of patients with COVID-19 domestic medicine “Favipiravir”, under the trade name “Replevin” will occupy on average no more than one week, said chief urologist of Ministry of health of Russian Federation, academician Dmitry Pushkar responsible for the implementation of the Protocol studies of the drug in Russia.
“the treatment regimen of patients with this drug has been developed. The average treatment will take no more than one week,” — said Pushkar RIA Novosti.
Preclinical trials of this drug in different animal models have shown that it acts on the virus for 5-6 days destroys it, said the gunner.
Earlier it was reported that a clinical trial is planned to be completed within 4-8 weeks, after which the documents will be filed for its registration.